Craif (Location: Bunkyo-ku, Tokyo, CEO: Ryuichi Onose, hereinafter referred to as “Craif”) announced that the number of medical institutions that have installed “miSignal®︎,” a cancer screening test for early detection of cancer risk based on urinary microRNA, achieved 200 as of October 2022. Craif will continue to strengthen its partnerships with medical institutions nationwide, and will widely deliver new approaches for early detection and optimization of treatment of various diseases to people, thereby realizing our mission “To Ensure Lifelong Health for Everyone.”